Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 16, 2025 in Zenas BioPharma, Inc. Lawsuit - ZBIO

Core Viewpoint - A class action securities lawsuit has been filed against Zenas BioPharma, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's September 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud related to Zenas BioPharma's IPO [2]. - The complaint alleges that Zenas BioPharma materially overstated its ability to fund operations using existing cash and expected net proceeds from the IPO, leading to false and misleading public statements [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Zenas BioPharma during the relevant time frame have until June 16, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].